¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"insulin convulsive therapy combined"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 3
¿µ¹® speech therapy ÇÑ±Û ¾ð¾îÄ¡·á
¼³¸í   
  ¸»À» Á¤È®ÇϰԠ¹ßÀ½ÇÒ ¼ö ¾ø°Å³ª ´õµë´Â È¯ÀÚ¿¡°Ô ¹ßÀ½, ´ëÈ­ µûÀ§ÀÇ ÈÆ·ÃÀ» Àü¹®ÀûÀ¸·Î ÇàÇϴ ġ·á¹ý. 
¿µ¹® therapy ÇÑ±Û ¿ä¹ý
¼³¸í   
  º´À» ³´°Ô Çϴ °Í ¶Ç´Â ±× ¹æ¹ý.
¿µ¹® gene therapy ÇÑ±Û À¯ÀüÀÚ¿ä¹ý
¼³¸í   
  À¯Àüº´À» Ä¡·áÇÒ ¸ñÀûÀ¸·Î, Á¤»óÀûÀ¸·Î ±â´ÉÇϴ ´ÜÀÏÀ¯ÀüÀڠȤÀº º¹¼öÀ¯ÀüÀÚ¸¦ ¾î¶² ±â¿ø¿¡¼­ ¾ò¾î³»¾î »ý¼¼Æ÷¿¡ µµÀÔÇϴ °Í. À¯Àü¹°ÁúÀº À¯ÀüÀÚ»ðÀÔ Á¶ÀÛ¿¡ ÀÇÇØ ¼ö¿ë¼¼Æ÷¿¡·Î µµÀԵȴÙ. Áï, À¯ÀüÀÚ¸¦ ³¢¿ö ³ÖÀº »õ·Î¿î ¼¼Æ÷¸¦ »ç¿ëÇϴ ġ·á·Î¼­ 1980³â ¹Ì±¹ÀÇ ÇÐÀÚ°¡ ÁöÁßÇØºóÇ÷ȯÀÚ¿¡°Ô °­ÇàÇÏ¿© ºñÆÇÀ» ¹Þ¾ÒÁö¸¸, ¹Ì±¹ ±¹¸³º¸°Ç¿¬±¸¼Ò´Â 1990³â 9¿ù ¾Æµ¥³ë½Å µ¥¾Æ¹Ì³ª¾ÆÁ¦(adenosine deaminase, ADA) °áÇÌÁõ È¯ÀÚÀÇ ¸²ÇÁ±¸¿¡ ADA À¯ÀüÀÚ¸¦ ³¢¿ö ³Ö´Â Ä¡·á¸¦ ½ÃÀÛÇÑ ÀÌ·¡ ÇöÀç´Â ¾ÏÀ» Æ÷ÇÔÇÑ ¸¹Àº Áúº´µéÀ» Ä¡·áÇϴ ¸ñÀûÀ¸·Î ¾²ÀδÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • insulin clamp
    Àν¶¸°Å¬·¥ÇÁ
  • insulin receptor
    Àν¶¸°¼ö¿ëü
  • insulin receptor substrate-1
    Àν¶¸°¼ö¿ëü±âÁú-1
  • insulin resistance
    Àν¶¸°ÀúÇ×, Àν¶¸°³»¼º
  • insulin sensitivity index
    Àν¶¸°¹Î°¨Áö¼ö
  • insulin shock
    Àν¶¸°¼îÅ©
  • insulin-dependent
    Àν¶¸°ÀÇÁ¸-
  • insulin-dependent diabetes
    Àν¶¸°ÀÇÁ¸´ç´¢º´
  • insulin-induced hypoglycemia
    Àν¶¸°À¯µµÀúÇ÷´ç(Áõ)
  • insulin-like activity
    Àν¶¸°À¯»çȰ¼ºµµ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • insulin-resistant diabetes
    Àν¶¸°ÀúÇ×´ç´¢º´
  • insulin-to-glucose ratio
    Àν¶¸°´ëÆ÷µµ´çºñ
  • intermediate-acting insulin
    Áß°£ÀÛ¿ëÀν¶¸°
  • long acting insulin
    Áö¼ÓÀÛ¿ëÀν¶¸°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • combined examination
    (¢¡bimanual examination) µÎ¼ÕÁøÂû, ³»Áø
  • combined hyperlipidemia
    º¹ÇÕ°íÁöÁúÇ÷Áõ
  • combined immunodeficiency
    º¹Çո鿪°áÇÌ
  • combined impression
    ¿¬ÇÕÀλó
  • combined nevus
    º¹ÇÕ¸ð¹Ý
  • combined pregnancy
    °âÇÑÀÓ½Å
  • combined scintiscan
    º´Çսů¼½ºÄµ, º´ÇÕ¼¶±¤½ºÄµ
  • combined sclerosis
    (¢¡subacute combined degeneration) ¾Æ±Þ¼º¿¬ÇÕº¯¼º
  • combined sensation
    º¹ÇÕ°¨°¢
  • combined version
    º¹ÇÕȸÀü(¼ú), º¹ÇÕžÆÈ¸Àü
  • combined immunodeficiency disease
    º¹Çո鿪°áÇ̺´
  • combined immunodeficiency syndrome
    º¹Çո鿪°áÇÌÁõÈıº
  • combined manual reposition
    µ¿¹Ýµµ¼öÁ¤º¹
  • combined plantar sign
    ¿¬Çչ߹ٴÚ¡ÈÄ
  • combined system disease
    º¹ÇÕ°èÅ뺴
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • protamin(e) zinc insulin
    ÇÁ·ÎŸ¹Î¾Æ¿¬ Àν¶¸°.
  • Chelation therapy
    ų·¹ÀÌÆ® ¿ä¹ý
  • ECT=Electroconvulsive Therapy
    Àü±â°æ·Ã¿ä¹ý
  • EST See Electroshock therapy
    Àü±âÃæ°Ý¿ä¹ý(ï³Ñ¨õú̪èþÛö)
  • Gene therapy
    À¯ÀüÀÚÄ¡·á(ö½Öû)
  • RePUVA therapy
    ·¹Æ¼³ëÀ̵å+PUVA
  • activity therapy
    Ȱµ¿¿ä¹ý(¡­èþÛö).
  • activity therapy
    Ȱµ¿ ¿ä¹ý
  • acupuncture therapy
    ħ¼ú¿ä¹ý.
  • adaptive radiation therapy
    ÀûÀÀ¹æ»ç¼±Ä¡, ¼øÀÀ¹æ»ç¼±Ä¡·á
  • adjuvant therapy
    º¸Á¶¿ä¹ý.
  • adjuvant therapy
    º¸Á¶¿ä¹ý, º¸Á¶Ä¡·á
  • androgen therapy
    ³²¼ºÈ£¸£¸ó ¿ä¹ý
  • antiandrogenic therapy
    Ç׳²¼ºÈ£¸£¸ó¿ä¹ý.
  • anticoagulant therapy
    Ç×ÀÀ°í¿ä¹ý.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • combined immunodeficiency
  • combined immunodeficiency disease
    º¹ÇÕÇü¸é¿ª°áÇÌÁúȯ
  • combined immunodeficiency disease
    º¹ÇÕÇü ¸é¿ª°áÇÌÁúȯ
  • combined immunodeficiency syndrome
    º¹ÇÕÇü ¸é¿ª°áÇÌ ÁõÈıº
  • combined immunodeficiency syndrome
    º¹ÇÕÇü¸é¿ª°áÇÌÁõ(Èıº)
  • combined impression
    ¿¬ÇÕÀλó(æáùêìÔßÚ).
  • combined manual reposition
    ½ÖÇÕ¿ë¼öȯ³³¹ý(äªùêéÄâ¢ü½Ò¡Ûö).
  • combined neck dissection
    Àϰý¼º °æºÎȮû¼ú(Àϰý¼º ºÎȮû¼ú).
  • combined nevus
  • combined nystagmus
    º¹ÇÕ¾ÈÁø
  • combined pelvimetry
    º¹ÇÕ¼º °ñ¹Ý°èÃø¹ý.
  • combined plantar sign
    ¿¬ÇÕ¼º Á·Àú¡ÈÄ(æáùêàõðëî¼ó£ý¦).
  • combined podalic version
    º¹ÇÕ¼º Á·ºÎÀÌ¿ëȸÀü¼ú, ½ÖÇÕÁ·À§È¸Àü¼ú.
  • combined scintiscan
    º´Çսů¼½ºÄµ.
  • combined sclerosis
    º´ÇÕ°æÈ­Áõ(ܱùê Ìãûùñø).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
conv convalescence, convalescent, convalescing; convergence, convergent; convulsions, convulsive
GMCD grand mal convulsive disorder
CCT carotid compression tomography; central conduction time; cerebrocranial trauma; chocolate-coated tab...
CDT carbohydrate-deficient transferrin; carbon dioxide therapy; Certified Dental Technician; children's ...
CHT chemotherapy; combined hormone therapy; contralateral head turning
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CHL Combined hyperlipidemia
CID Combined immunodeficiency
COC Combined oral contraceptive
CPHD Combined pituitary hormone deficiency
CSEA Combined spinal epidural anesthesia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • severe combined immunodeficiency
    ÁßÁõ º¹ÇÕ ¸é¿ª °áÇÌÁõ, ÁßÁõ È¥ÇÕ ¸é¿ª °áÇÌÁõ
  • acrylic splint therapy
    ¾ÆÅ©¸± ¾ÈÁ¤ ±³ÇÕ»ó Ä¡·á
  • active relaxation therapy
    ´Éµ¿ ÀÌ¿Ï ¿ä¹ý
  • adaptive radiation therapy
    ÀûÀÀ ¹æ»ç¼± Ä¡·á, ¼øÀÀ ¹æ»ç¼± Ä¡·á
  • adjunctive therapy
    ºÎ°¡ ¿ä¹ý
    ÁÖµÈ Ä¡·á °úÁ¤ ÀÌ¿ÜÀÇ Ãß°¡ Ä¡·á °úÁ¤.
  • adjuvant therapy
    º¸Á¶ ¿ä¹ý
  • anticoagulant therapy
    Ç×ÀÀ°í Ä¡·á, Ç×ÀÀ°í ¿ä¹ý
  • antimicrobial therapy
    Ç×±Õ ¿ä¹ý
  • atropine therapy
    ¾ÆÆ®·ÎÇÉ Ä¡·á, ¾ÆÆ®·ÎÇÉ ¿ä¹ý
  • aversion therapy
    Çø±â¿ä¹ý
    ¿øÇÏÁö ¾Ê´Â Çൿ ÆÐÅÏÀ» ºÒÄèÇÑ Àڱذú °áºÎ½ÃŰ´Â °Í. ¶Ç´Â ¿øÇÏÁö ¾Ê´Â ÇàÀ§·ÎºÎÅÍ ºÒÄèÇÑ ÀÚ±ØÀÌ »ý±âµµ·Ï ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÑ Ä¡·á.
  • behavior therapy
    Çൿ ¿ä¹ý, Çൿ Ä¡·á
    Á¤½Å°úÀû Ä¡·á ¹æ¹ýÀÇ Çϳª. ¹«ÀǽÄÀûÀÎ ¿ä¼Ò³ª ³»ºÎ °¥µî µîÀÇ ´«¿¡ º¸ÀÌÁö ¾Ê´Â °ÍÀ» ´ë»óÀ¸·Î ÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó Á÷Á¢ °üÂûÇÒ ¼ö ÀÖ´Â ÇൿÀ» ´ë»óÀ¸·Î Ä¡·áÇÑ´Ù. ƯÁ¤ ȯ°æÀ» ¼³Á¤Çϰí À̰Ϳ¡ ´ëÇØ¼­ ¹Ù¶÷Á÷ÇÑ ÇൿÀ» ÇÏ°Ô ¸¸µé¾î º¯È­½ÃŰ°í ½ÍÀº ÇൿÀ» °íÃijª°¡´Â ¹æ¹ýÀÌ´Ù. ÇнÀ ÀÌ·ÐÀ» ½Å°æÁõÀû ÇൿÀ̳ª ºÎÀûÀÀ Çൿ µîÀÇ ÀÌ»ó Çൿ¿¡ Àû¿ëÇϰí Çൿ º¯¿ëÀ» ²ÒÇÏ·Á´Â ÀÓ»ó½É¸®ÇÐÀû Ä¡·á¹ýÀÇ ÃÑĪ.
  • biofeedback therapy
    ¹ÙÀÌ¿ÀÇǵå¹é ¿ä¹ý
  • biologic therapy
    »ý¹°ÇÐÀû Á¦Á¦ ¿ä¹ý
  • biostimulation therapy
    »ýü ÀÚ±Ø Ä¡·á, »ýü ÀÚ±Ø ¿ä¹ý
  • cognitive therapy
    ÀÎÁö Ä¡·á, ÀÎÁö ¿ä¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
familial combined hyperlipidaemia <biochemistry, endocrinology> Inherited as a defective gene, this disorder is characterised by elevations in serum cholesterol and/or triglycerides.
There are often multiple types of lipoproteins (LDL) elevated in one family. This condition is associated with an increased risk of cardiovascular disease.
(27 Sep 1997)
amorphous insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
anti-insulin A factor, usually an antibody, which antagonises the action of insulin.
(05 Mar 2000)
anti-insulin antibody A serologic blood test that is used to detect antibodies to insulin. This test is performed in insulin dependent diabetics who exhibit insulin resistance. The presence of antibodies denotes a positive result.
(27 Sep 1997)
biphasic insulin <protein> A type of insulin that is a mixture of intermediate- and fast-acting insulin.
(09 Oct 1997)
receptors, insulin Cell surface proteins that bind insulin and trigger intracellular changes which influence the behaviour of cells. The best understood physiological consequence of insulin receptor activation is increased transport of glucose into most cells, which controls the rate of carbohydrate metabolism. The insulin receptor is a multifunctional protein complex that has intrinsic tyrosine kinase activity and is capable of autophosphorylation.
(12 Dec 1998)
receptors, insulin-like-growth factor I Specific proteins on or in cells to which insulin-like growth factor I (somatomedin c) binds and thereby modifies the function of the cells. These receptors contain transmembrane and cytosolic domains, bind igf-I preferentially, and have high-affinity sites for igf-II. The alpha-subunit has a mw of 130 kD and the beta subunit possesses tyrosine kinase activity.
(12 Dec 1998)
receptors, insulin-like-growth-factor II Specific proteins on or in cells to which insulin-like growth factor II and mannose-6-phosphate bind and thereby modify the function of the cells. These receptors have a mw of 250 kD and possess no tyrosine kinase activity.
(12 Dec 1998)
regular insulin A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours.
Synonym: globin insulin.
(05 Mar 2000)
regular insulin injection A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma.
Synonym: regular insulin injection.
(05 Mar 2000)
globin insulin A rapidly acting form of insulin which is a clear solution and may be administered intravenously as well as subcutaneously; may be mixed with longer acting forms of insulin to extend the duration of effect. Onset of effect occurs in 1/2 to 1 hour, peak effects are observed in 2 to 3 hours, and the duration of effect is about 5 to 7 hours.
Synonym: globin insulin.
(05 Mar 2000)
globin zinc insulin A sterile solution of insulin modified by the addition of zinc chloride and globin; it contains 40 or 80 units per ml; duration of action is about 18 hours.
Human insulin, a protein that has the normal structure of insulin produced by the human pancreas, prepared by recombinant DNA techniques and by semisynthetic processes.
Immunoreactive insulin (IRI), that portion of insulin in blood measured by immunochemical methods for the hormone; presumed to represent the free (unbound) and biologically active fraction of total blood insulin.
Isophane insulin, a modified form of insulin composed of insulin, protamine, and zinc; an intermediately acting preparation used for the treatment of diabetes mellitus.
Synonym: NPH insulin.
(05 Mar 2000)
crystalline insulin zinc suspension A long-acting insulin suspension, obtained from beef, with an approximate time of onset of 7 hours and a duration of action of 36 hours.
Synonym: crystalline insulin zinc suspension.
(05 Mar 2000)
prompt insulin zinc suspension Sterile suspension of insulin in buffered water for injection, modified by the addition of zinc chloride such that the solid phase of the suspension is amorphous; it contains 40 or 80 units per ml; the duration of action is equivalent to that of insulin injection.
Synonym: amorphous insulin zinc suspension, semilente insulin.
(05 Mar 2000)
protamine zinc insulin Insulin modified by the addition of protamine and zinc chloride; it contains 40 or 80 units per ml.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • reinforcement therapy
    ´Ù½Ã À×Å©¸¦ ¹¯È÷´Ù
  • shock therapy
    (Á¤½Åº´ÀÇ)Ãæ°Ý(Àü°Ý)¿ä¹ý
  • speech therapy
    ¾ð¾îÀå¾Ö ±³Á¤(¼ú) 
  • therapy
    Ä¡·á
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á